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ABSTRACT
Background. This study examined whether an innate
systemic inflammatory response (SIR) measured by com-
bination neutrophil to lymphocyte ratio (NLR) and
modified Glasgow Prognostic Score (mGPS) was associ-
ated with overall survival (OS) in patients with
esophagogastric cancer (EC) undergoing neoadjuvant
chemotherapy (NAC) followed by surgery.
Methods. Patients diagnosed with EC, managed with
NAC prior to surgery at a regional referral center, between
January 2010 and December 2015, were included. The
mGPS and NLR were calculated within 12 weeks before
NAC. Patients were grouped by combined NLR/mGPS
score into three groups of increasing SIR: NLR B 3
(n = 152), NLR[ 3 ? mGPS = 0 (n = 55), and NLR[
3 ? mGPS[ 0 (n = 32). Univariable and multivariable
Cox regression was used to analyse OS.
Results. Overall, 337 NAC patients were included, with
301 (89%) proceeding to surgery and 215 (64%) having R0
resection. There were 203 deaths, with a median follow-up
of those alive at censor of 69 months (range 44–114).
Higher combined NLR/mGPS score (n = 239) was asso-
ciated with poorer OS independent of clinical stage and
performance status (hazard ratio 1.28, 95% confidence
interval 1.02–1.61; p = 0.032), higher rate of progression
on NAC (7% vs. 7% vs. 19%; p = 0.003), and lower pro-
portion of eventual resection (80% vs. 84% vs. 53%;
p = 0.003).
Conclusions. The combined NLR/mGPS score was asso-
ciated with OS and initial treatment outcomes in patients
undergoing NAC prior to surgery for EC, stratifying sur-
vival in addition to clinical staging and performance status.
The host SIR may be a useful adjunct to multidisciplinary
decision making.
Esophagogastric cancers (ECs) are associated with poor
survival,1 varying between 40% and 50% at 3 years for
squamous cell carcinoma and adenocarcinoma, respec-
tively, when treated with curative intent.2 Many patients
present with advanced disease at diagnosis, decreasing the
overall 5-year survival from 39% for localized disease to
4% for disease with distant metastases.3 Currently, patients
with operable tumors are offered surgery with curative
intent, often preceded by neoadjuvant chemotherapy
(NAC). These patients undergo rigorous anesthetic
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assessment and cardiopulmonary exercise testing (CPET)
prior to surgery. High rates of postoperative morbidity and
mortality remain.4–6
Unfortunately, tumor recurrence is common even after
treatment with curative intent, and the development of
recurrent disease typically occurs within 2 years of surgery
in 50% of resected patients.7 The main determinants of
prognosis are pathological characteristics of the resected
tumor specimen, including TNM stage, tumor differentia-
tion, lymphovascular invasion (LVI), and resection margin
involvement8,9; however, pretreatment clinical staging is
also of prognostic importance.
In recent years, the presence of a preoperative innate
systemic inflammatory response (SIR) has also been rec-
ognized as a potentially important prognostic marker in
EC, in both palliative and curative settings.10 It is postu-
lated to be related to the upregulation or inappropriate
activation of the innate immune response, which sup-
presses the more useful anticancer adaptive response.11 It is
therefore speculated that the presence of an innate SIR,
represented by measurements of the acute-phase reactants
C-reactive protein (CRP) and albumin in the form of the
modified Glasgow Prognostic Score (mGPS) may be useful
to identify EC patients who will have higher rates of
postoperative morbidity and poorer prognosis following
resection of locally advanced disease.12 Another com-
monly used measure of the SIR is the neutrophil to
lymphocyte ratio (NLR).13 Recently, it has been proposed
that mGPS and NLR be used together in a combined
prognostic SIR score, providing gross and clinically
available information relating to cytokine production and
protein turnover, along with leukocyte and marrow
responses.14
This study aimed to assess the combined NLR/mGPS
score method prior to commencing NAC for EC patients
treated with curative intent. Prognostic stratification with
such a score, especially used together with clinical TNM
staging, may be of value to prevent individuals with a
particularly poor prognosis from undergoing chemother-
apy, and then major surgery, resulting in significant
morbidity, while also identifying those who would benefit
from an aggressive approach.
PATIENTS AND METHODS
Patients
This study included patients with EC treated with initial
curative intent in the National Health Service (NHS)
Greater Glasgow and Clyde (NHSGGC) and NHS Forth
Valley (NHSFV) areas between January 2010 and
December 2015. Patients not included were those who
underwent potentially curative surgery without NAC, rad-
ical chemoradiation without any plan for surgery, those
diagnosed with metastatic disease, and those who received
palliative first-line treatment such as palliative
chemotherapy and/or radiotherapy and any other palliative
intervention, including laser, stent and dilatation.
All patients were discussed at a specialist multidisci-
plinary esophagogastric meeting following diagnosis, prior
to NAC, prior to surgery, and then following surgery. NAC
was offered to patients with an Eastern Cooperative
Oncology Group (ECOG) score of 0–2 with clinical T3-4
disease or any clinical node-positive disease, or where
there were concerns regarding possible margin-threatening
disease at staging.
During staging, all patients underwent diagnostic upper
gastrointestinal endoscopy followed by contrast computed
tomography (CT) of the thorax, abdomen and pelvis.
Positron emission tomography (PET)/CT was used in the
majority of esophageal (94%) and junctional tumors (67%),
and in a small proportion of gastric tumors (21%). Diag-
nostic laparoscopy, including washings-based cytology,
was undertaken in 77% of esophageal tumors and 86% of
junctional and gastric tumors. Endoscopic ultrasound was
not used routinely but was used in a focused manner
in situations of diagnostic or luminal staging doubt. No
included patients underwent esophageal stenting, laser, or
dilatation prior to treatment; however, a fine-bore enteral
feeding tube was placed endoscopically in some cases of
near-obstructing tumor.
All patients received NAC in either NHSGGC or
NHSFV, and those who proceeded to surgery were oper-
ated on in a single tertiary referral teaching hospital
(Glasgow Royal Infirmary). All NAC regimens used
included a combination of a platinum-based drug plus
5-fluorouracil or capecitabine, as well as epirubicin where
tolerated. There was a median of 8 weeks between the end
of treatment and surgery, during which restaging occurred.
Patients with EC underwent Ivor Lewis, left thora-
coabdominal, three-stage, or transhiatal esophagectomy,
dependent on tumor site and surgeon preference. Patients
with gastric cancer received either partial or total gastrec-
tomy. At the induction of anesthesia, prophylactic
antibiotics were administered. Venous thromboprophy-
laxis, in the form of pneumatic compression stockings and
subcutaneous low molecular weight heparin, was given as
per unit policy. During the initial postoperative recovery
period, all patients were admitted to either the intensive
care unit or surgical high dependency unit. Those patients
who made sufficient progress were then transferred to the
surgical ward. Patients were kept nil by mouth until the
integrity of the anastomosis was confirmed using a water-
soluble contrast swallow test, typically between postoper-
ative days 6 and 9. During this period, nutrition was given
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either parenterally via a tunneled central venous catheter or
via a feeding jejunostomy. Patients were reviewed by the
surgical team daily and had daily postoperative blood tests,
including full blood count (FBC), CRP, and albumin. In-
vestigation and management of possible postoperative
complications was at the discretion of the clinical team.
This study was approved by the local Caldicott Guardian
and Research Ethics Committee (19/SC/0653).
METHODS
The dataset was obtained from two prospectively
maintained clinical databases: the Beatson Oncology
Centre Chemocare database and the esophagogastric unit’s
clinical outcomes audit database, which were used to
identify patents who had NAC and surgery, respectively.
The Community Health Index (CHI) number was used as
the linkage variable to merge the data. Clinicopathological
data were collected from electronic case notes, including
age, sex, body mass index (BMI), smoking, tumor site,
clinical and pathological TNM staging, preoperative in-
vestigations, hematological results, and inflammatory
markers.
Pretreatment physical fitness was determined primarily
based on performance status according to the ECOG score,
oxygen uptake at the aerobic threshold (VO2 AT), and
maximal oxygen uptake (VO2 peak) measured by CPET.
CPET served as a semiquantitative functional assessment
of cardiopulmonary reserve and can be used to predict the
risk of perioperative morbidity and mortality. Thresholds
of VO2 AT\ 11 mL/kg/min and VO2 peak\ 19 mL/kg/
min were set, values below which were considered as
having a certain level of cardiopulmonary dysfunction.15
The mGPS and NLR were used to quantify the SIR of
the patients. The mGPS was calculated for each patient
using serum CRP and albumin levels obtained from bio-
chemistry reports. CRP and albumin were measured using
an Abbot Architect (Abbot UK) multianalyzer. The scoring
system for mGPS is as follows: CRP B 10 mg/L = 0;
CRP[ 10 mg/L and albumin C 35 g/L = 1; and CRP[
10 mg/L and albumin\ 35 g/L = 2.12 A higher score
reflects a more profound SIR. NLR was calculated by the
number of neutrophils divided by the number of lympho-
cytes using values obtained from FBCs. A threshold of
NLR[ 3 was used to indicate a significantly elevated
SIR.13 Prechemotherapy mGPS and NLR were calculated
using reports at up to 3 months prior to chemotherapy and
before any intervention such as diagnostic laparoscopy, or
at the commencement of chemotherapy. Patients were
grouped by combined NLR and mGPS into three groups,
from least to most inflamed: NLR B 3, NLR[ 3 ?
mGPS = 0, NLR[ 3 ? mGPS[ 0.
Patient’s staging CT scans were used to obtain the
appropriate body composition measurement using ‘ImageJ’
(version 1.51, NIH, USA), a freeware validated software
program. Axial CT slices were obtained at the level of the
third lumbar vertebra. Region of interest (ROI) area mea-
surements were skeletal muscle area (SMA) expressed as
cm2 using standard Hounsfield unit (HU) ranges: - 29 to
? 150 HU. SMA was then normalized to height
(m) squared to create the skeletal muscle index (SMI),
expressed as cm2/m2. Sarcopenia was defined as SMI\
52.3 cm2/m2 if the BMI was\ 30 kg/m2, or SMI\ 54.3
cm2/m2 if the BMI was C 30 kg/m2 in male patients; and
SMI\ 38.6 cm2/m2 if the BMI was\ 30 kg/m2, or
SMI\ 46.6 cm2/m2 if the BMI was C 30 kg/m2 in female
patients.16
Statistical Analysis
Data analysis was performed in an anonymized manner
using IBM SPSS software version 24 (SPSS, Inc., Chicago,
IL, USA). The Pearson Chi square test was used to
examine the associations between categorical variables,
and the Chi square test for linear trend was used for ordered
variables with multiple categories. Cox regression was
used for univariable and then multivariable survival anal-
ysis for those variables found to be statistically
significantly associated with overall survival (OS) at uni-
variable analysis. All regressions were performed using a
backward conditional model. Kaplan–Meier analysis and
the log-rank test were used to examine OS pooled across
clinical stage and performance status subgroups. OS was
defined as the time from the date of diagnosis to the date of
death due to any cause. A p value\ 0.05 (two-sided) was
considered statistically significant in all tests.
RESULTS
Patients
The study included 337 patients (Table 1), with the
majority being male (n = 240, 71%) and over 65 years of
age (n = 175, 54%); 311 had adenocarcinoma at biopsy
(93%), with 22 having squamous cell carcinoma (7%).
There were 94 esophageal cancers (29%), 205 junctional
cancers (62%), and 29 gastric cancers (9%). The majority
had clinical T3-4 disease (n = 215, 65%) and clinical node-
positive disease (n = 193, 59%) at pretreatment staging.
The majority were reported to be ECOG performance
status 0 or 1 prior to commencing NAC (n = 313, 96%).
All 337 patients received NAC, of whom 298 (88%) had
one of the following regimens: epirubicin, cisplatin/carbo-
platin/oxaliplatin, 5-fluorouracil, capecitabine (ECF/ECX/
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EOF) and 39 patients (12%) had cisplatin and 5-fluo-
rouracil/capecitabine. The median time between the
completion of NAC and surgery was 8 weeks (interquartile
range 7–9).
Of the 337 patients, 215 (64%) had an R0 resection, 55
(16%) had an R1 or R2 resection, 31 (9%) had trial dis-
section but were found to be irresectable, 26 (8%) did not
proceed to surgery due to disease progression during NAC,
and 10 (3%) did not proceed to surgery due to a significant
medical complication or toxicity during NAC (Fig. 1).
During the follow-up period there were 203 deaths (60%),
with 183 of these deaths caused by EC. The median survival
of the cohort as a whole was 37 months (interquartile
range 25–48). The median follow-up of those alive at the
time of censoring was 69 months (range 44–114).
Creation of Combined Neutrophil to Lymphocyte Ratio
(NLR)/Modified Glasgow Prognostic Score (mGPS)
Score
Pretreatment mGPS could be calculated for 264 patients,
NLR could be calculated for 293 patients, and was avail-
able for both in 239 patients, with survival data for 231
patients. Combining mGPS and NLR (Table 2) signifi-
cantly stratified the 5-year percentage of OS more
effectively than either measure of the SIR alone
TABLE 1 Clinicopathological characteristics among






Age, years \ 65 149 (46)
65–75 151 (47)
[ 75 24 (7)
Sex Male 240 (71)
Female 97 (29)
BMI, kg/m2 \ 20 16 (5)
20–24 103 (33)
25–29 127 (40)
[ 29 69 (22)
Smoking Never 109 (34)
Ex-smoker 148 (46)
Current 63 (20)
ECOG 0 234 (72)
1 79 (24)
2 14 (4)
VO2 AT, mL/kg/min [n = 255] \ 11 96 (38)
C 11 159 (62)
VO2 peak, mL/kg/min [n = 204] \ 19 106 (52)
C 19 98 (48)




CT sarcopeniaa No 107 (36)
Yes 187 (64)
Tumor characteristics
Tumor site Esophageal 94 (29)
Gastric 29 (9)
Junctional 205 (62)









mGPS [n = 264] 0 194 (73)
1 41 (16)
2 29 (11)
NLR [n = 293] \ 3 183 (54)




















BMI body mass index, ECOG Eastern Cooperative Oncology Group
performance status, VO2 AT oxygen uptake at the aerobic threshold,
VO2 peak maximal oxygen uptake, cTNM stage clinical TNM stage,
mGPS preoperative modified Glasgow Prognostic score, NLR neu-
trophil to lymphocyte ratio, NAC neoadjuvant chemotherapy, CT
computed tomography, SMI skeletal muscle index
aCT sarcopenia was defined as SMIb\ 52.3 cm2/m2 if the BMI
was\ 30 kg/m2, or\ 54.3 cm2/m2 if the BMI was C 30 kg/m2 in
men; and SMI\ 38.6 cm2/m2 if the BMI was\ 30 kg/m2, or\
46.6 cm2/m2 if the BMI was C 30 kg/m2 in women
bSMI (cm2/m2) was defined as the skeletal muscle area (cm2) mea-
sured from the axial CT slice at the L3 vertebral level/height (m)2
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(p = 0.012). The data suggested that those with an NLR
B 3 have a similar 5-year percentage of OS regardless of
the mGPS (0 = 47%, 1 = 55%, 2 = 45%), whereas those
with an NLR[ 3 had a poorer 5-year percentage of OS
with increasing mGPS (0 = 34%, 1 = 29%, 2 = 21%).
Therefore, a combined NLR/mGPS score was created for
three groups: NLR B 3 (n = 152), NLR[ 3 ? mGPS = 0
(n = 55), and NLR[ 3 ? mGPS[ 0 (n = 32).
Association Between Combined NLR/mGPS Score
and Clinicopathological Factors
When patient demographic, clinical, and pathological
factors were considered, there were no statistically significant
associations with the combined NLR/mGPS score (Table 3).
Association Between Combined NLR/mGPS Score
and Initial Treatment Outcomes
The combined NLR/mGPS score was significantly
associated (p = 0.031) with the initial treatment outcome
(Table 3). As the degree of inflammation increased (from
NLR B 3 to NLR[ 3 ? mGPS = 0, then NLR[ 3 ?
mGPS[ 0), there was a significantly higher rate of
progression on NAC (7% vs. 7% vs. 19%), significantly
higher rate of medical complication or major toxicity
preventing patients reaching surgery (3% vs. 5% vs. 12%),
and lower proportion of eventual R0 resections (62% vs.
60% vs. 44%).
Association Between Combined NLR/mGPS Score
and Overall Survival
At univariable Cox regression (Table 4), ECOG
(p = 0.001), combined NLR/mGPS score (p = 0.006),
clinical TNM stage (p\ 0.001), and R0 resection
(p\ 0.001) were significantly associated with OS. At
multivariable Cox regression, the combined NLR/mGPS
score remained independently prognostic (hazard ratio
[HR] 1.28, 95% CI 1.02–1.61; p = 0.032), along with
ECOG (HR 1.61, 95% CI 1.21–2.13; p = 0.001), cTNM
(HR 1.34, 95% CI 1.04–1.73; p = 0.025), and R0 resection
(HR 0.24, 95% CI 0.18–0.33; p\ 0.001).
When all patients who began treatment with curative
intent (planned NAC then surgery), with a calculable
combined NLR/mGPS score, were considered, use of the
combined NLR/mGPS score stratified 5-year OS in addi-
tion to clinical TNM stage and ECOG (Table 5). Five-year
OS was stratified from 66% in those with cTNM stage 1–2
disease and the lowest combined NLR/mGPS score, to
22% in those with cTNM stage 3–4 disease and the highest
combined NLR/mGPS score (p\ 0.001). Five-year OS
was stratified from 53% in those with an ECOG perfor-
mance status score of 0 and the lowest combined NLR/
mGPS score, to 14% in those with an ECOG performance
status score of 1–2 and the highest combined NLR/mGPS
score (p\ 0.001).
When those patients from this group who went on to R0
resection were considered (Table 6), the use of the com-
bined NLR/mGPS score stratified 5-year OS in addition to
pathological TNM stage. Five-year OS was stratified from











mGPS n = 264
NLR n = 293







score n = 239
Resected
R0 n = 215
R1/2 n = 55
Direct surgery
n = 92
FIG. 1 Patient inclusion process. SIR systemic inflammatory
response, mGPS preoperative modified Glasgow Prognostic score,
NLR neutrophil to lymphocyte ratio
TABLE 2 Systemic inflammatory response measures associated
with overall survival in esophagogastric cancer patients prior to
neoadjuvant chemotherapy with initial curative intent
Proportion of patients surviving 5 years after diagnosis
mGPS NLR\ 3 NLR C 3 p Value
n 5-year % OS (SE) n 5-year % OS (SE)
0 116 47 (5) 55 34 (6)
1 20 55 (11) 17 29 (11)
2 11 45 (15) 14 21 (11)
0.012
mGPS preoperative modified Glasgow Prognostic score, NLR neu-
trophil to lymphocyte ratio, OS overall survival, SE standard error
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TABLE 3 Clinicopathological characteristics of esophagogastric cancer patients undergoing treatment with curative intent, grouped by
combined neutrophil to lymphocyte ratio and modified Glasgow Prognostic Score
Characteristic Combined NLR/mGPS p Value
NLR\ 3 NLR[ 3 ? mGPS = 0 NLR[ 3 ? mGPS[ 0
N 152 (64) 55 (23) 32 (13) –
Patient characteristics
Age, years \ 65 74 (49) 25 (46) 10 (31) 0.422
65–75 61 (40) 26 (47) 20 (63)
[ 75 17 (11) 4 (7) 2 (6)
Sex Male 106 (70) 38 (69) 25 (78) 0.447
Female 46 (30) 17 (31) 7 (22)
BMI, kg/m2 \ 20 4 (3) 4 (8) 2 (7) 0.092
20–24 52 (36) 15 (30) 13 (47)
25–29 57 (40) 19 (38) 11 (39)
[ 29 31 (21) 12 (24) 2 (7)
Smoking Never 48 (32) 14 (27) 12 (43) 0.990
Ex-smoker 69 (46) 24 (46) 9 (32)
Current 32 (22) 14 (27) 7 (25)
ECOG 0 113 (76) 34 (63) 22 (76) 0.963
1 27 (18) 18 (33) 7 (24)
2 9 (6) 2 (4) 0 (0)
VO2 AT, mL/kg/min \ 11 41 (36) 16 (37) 11 (44) 0.468
C 11 74 (64) 27 (63) 14 (56)
Anemia No 107 (70) 34 (62) 18 (65) 0.081
Yes 45 (30) 21 (38) 14 (44)
CT sarcopeniaa No 47 (35) 16 (35) 5 (19) 0.175
Yes 86 (65) 30 (65) 21 (81)
Tumor characteristics
Tumor site Esophageal 41 (27) 15 (28) 14 (44) 0.186
Gastric 14 (9) 35 (65) 15 (47)
Junctional 96 (64) 4 (7) 3 (9)
Histology Adenocarcinoma 109 (92) 43 (96) 14 (82) 0.553
SCC 10 (8) 2 (4) 3 (18)
cTNM stage 1 19 (12) 2 (4) 2 (6) 0.295
2 33 (22) 16 (29) 7 (22)
3 93 (62) 34 (63) 22 (69)
4A 6 (4) 2 (4) 1 (3)
Initial treatment outcome
Surgery—R0 94 (62) 33 (60) 14 (44) 0.031
Surgery—R1/R2 27 (18) 13 (24) 3 (9)
Surgery—Inoperable 16 (10) 2 (4) 5 (16)
Progression on NAC 10 (7) 4 (7) 6 (19)
NAC complication/major
toxicity
5 (3) 3 (5) 4 (12)
Data are expressed as n (%)
BMI body mass index, CT computed tomography, ECOG Eastern Cooperative Oncology Group performance status, VO2 AT oxygen uptake at
the aerobic threshold, cTNM stage clinical TNM stage, mGPS preoperative modified Glasgow Prognostic score, NLR neutrophil to lymphocyte
ratio, NAC neoadjuvant chemotherapy, SCC squamous cell carcinoma, SMI skeletal muscle index
aCT sarcopenia was defined as SMIb\ 52.3 cm2/m2 if the BMI was\ 30 kg/m2, or\ 54.3 cm2/m2 if the BMI was C 30 kg/m2 in men; and
SMI\ 38.6 cm2/m2 if the BMI was\ 30 kg/m2, or\ 46.6 cm2/m2 if the BMI was C 30 kg/m2 in women
bSMI (cm2/m2) was defined as the skeletal muscle area (cm2) measured from the axial CT slice at the L3 vertebral level/height (m)2
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77% in those with pTNM stage 1–2 disease and the lowest
combined NLR/mGPS score, to 0% in those with pTNM
stage 3–4 disease and the highest combined NLR/mGPS
score (p\ 0.001).
Finally, when the small number of patients from this
group who did not go on to R0 resection were considered,
the combined NLR/mGPS score did not provide additional
prognostic stratification in addition to ECOG performance
status (p = 0.209).
TABLE 4 Cox regression of factors associated with overall survival in esophagogastric cancer patients prior to neoadjuvant chemotherapy with
initial curative intent
Variables Univariable HR (95% CI) p Value Multivariable HR (95% CI) p Value
Age 1.11 (0.89–1.39) 0.359 – –
ECOG 1.51 (1.19–1.93) 0.001 1.61 (1.21–2.13) 0.001
Smoking 1.02 (0.84–1.25) 0.814 – –
BMI, kg/m2 0.88 (0.74–1.04) 0.135 – –
VO2 AT\ 11, mL/kg/min 1.34 (0.97–1.85) 0.073 – –
Anemia 1.28 (0.94–1.74) 0.119 – –
CT sarcopeniaa 1.02 (0.74–1.39) 0.922
Combined NLR/mGPS 1.45 (1.12–1.88) 0.006 1.28 (1.02–1.61) 0.032
cTNM stage 1.53 (1.22–1.91) \ 0.001 1.34 (1.04–1.73) 0.025
R0 resection 0.24 (0.18–0.33) \ 0.001 0.24 (0.18–0.33) \ 0.001
HR hazard ratio, CI confidence interval, ECOG Eastern Cooperative Oncology Group performance status, BMI body mass index, VO2 AT oxygen
uptake at the aerobic threshold, CT computed tomography, mGPS preoperative modified Glasgow Prognostic score, NLR neutrophil to lym-
phocyte ratio, cTNM stage clinical TNM stage, SMI skeletal muscle index
*CT sarcopenia was defined as SMIb\ 52.3 cm2/m2 if the BMI was\ 30 kg/m2, or\ 54.3 cm2/m2 if the BMI was C 30 kg/m2 in men; and
SMI\ 38.6 cm2/m2 if the BMI was\ 30 kg/m2, or\ 46.6 cm2/m2 if the BMI was C 30 kg/m2 in women
bSMI (cm2/m2) was defined as the skeletal muscle area (cm2) measured from the axial CT slice at the L3 vertebral level/height (m)2
TABLE 5 Overall survival following initiation of treatment with curative intent based on pretreatment clinical TNM stage, ECOG performance
status, and combined NLR/mGPS
ECOG performance status p Value
0 1–2
n 5-year OS, % (SE) n 5-year OS, % (SE)
Combined NLR/mGPS
NLR\ 3 110 53 (5) 34 35 (8)
NLR[ 3 ? mGPS = 0 34 35 (8) 20 35 (11)




n 5-year OS, % (SE) n 5-year OS, % (SE)
Combined NLR/mGPS
NLR\ 3 51 66 (7) 95 37 (5)
NLR[ 3 ? mGPS = 0 18 56 (12) 36 25 (7)
NLR[ 3 ? mGPS[ 0 8 38 (17) 23 22 (9)
\ 0.001
ECOG Eastern Cooperative Oncology Group performance status, mGPS preoperative modified Glasgow Prognostic score, NLR neutrophil to
lymphocyte ratio, OS overall survival, SE standard error
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DISCUSSION
The present study reports that a combination of the
systemic inflammatory scoring systems NLR and mGPS is
associated with OS when measured prior to commencing
NAC with curative intent in patients with ECs. It was also
significantly associated with initial treatment outcomes,
including the proportion of patients with disease progres-
sion during NAC, with major toxicity or medical
complications during NAC, and the proportion of patients
eventually undergoing a successful resection. Furthermore,
the addition of the combined NLR/mGPS score to the
ECOG performance status, as well as early clinical stage
disease, effectively stratified 5-year OS in this group of
patients. The use of such a readily clinically available
measure of the SIR along with clinical staging and per-
formance status may be helpful in identifying those
patients likely to have a very poor prognosis despite
treatment with curative intent, and therefore in whom
symptomatic management may be more appropriate.
Conversely, this method of staging both the tumor and the
host may help to identify those most likely to benefit from
aggressive treatment.
Both mGPS and NLR have been widely studied in a
variety of solid tumors, each being shown to provide
prognostication independent of disease stage.13 Indeed, the
presence of systemic inflammation, by an increasing
number of scores and ratios, is almost universally associ-
ated with poor prognosis, including in EC.17 It is
hypothesized that the inflammatory response is driven by
host–tumor interactions,18 and that along with potentiation
of a prometastatic environment,19 a relative suppression of
the host adaptive immune system leads to disease recur-
rence and death in these patients.20 The mGPS combines
the acute-phase proteins CRP and albumin, and therefore
can be seen as a clinically readily available marker of
cytokine production and protein metabolism during an
SIR.21 In contrast, the NLR provides a gross picture of the
cellular response to the inflammatory stimulus.22 As such,
previous attempts have been made to combine the two
systems, perhaps providing an even greater overview of the
inflammatory response, with success at prognostication in
colorectal cancer.14 Indeed, as far as the authors are aware,
at present this is the first paper that externally validates the
method of combining the NLR and the mGPS. It is there-
fore also the first to apply it to a different cancer type.
Although the measurement of systemic inflammation
has until now provided prognostic information in solid
tumors, its clinical use has been less clear. However,
recently, the combination of mGPS and TNM staging has
been shown to effectively stratify survival in colorectal
cancer patients,23 while the combination of mGPS and
ECOG performance status has been used to stratify both
survival and symptom reporting in patients with palliative
disease.24 The routine incorporation of readily available
measures of systemic inflammation in the clinical setting
might therefore be used during the staging process to allow
for both staging of the tumor and the host.25 This might
allow multidisciplinary teams to offer an optimal treatment
plan, preventing high morbidity aggressive treatment for
those patients deemed to have a very poor prognosis when
host and tumor factors are considered. Furthermore, as the
possibility of treatments directed at the host inflammatory
response to cancer becomes clearer, it may be that such a
method identifies patients for whom additional treatment
options to negate the impact of the innate inflammatory
response are available.26,27 Examples of this in the preop-
erative setting might include non-specific anti-
inflammatory treatments or more specific immunothera-
pies, although current evidence in the neoadjuvant setting
does not extend to ECs and is focused primarily on
checkpoint inhibitors such as nivolumab.28,29
The main limitations of the present study were that it
was carried out in a single center and with a relatively
small sample size. Further validation from future multi-
center studies in a larger independent patient cohort is
needed. The inclusion of esophageal, junctional, and gas-
tric cancers, as well as a small number of squamous
TABLE 6 Overall survival
following R0 resection based on
pathological TNM stage and
combined NLR/mGPS
Pathological TNM stage p Value
0–2 3–4A
n 5-year OS, % (SE) n 5-year OS, % (SE)
Combined NLR/mGPS
NLR\ 3 69 77 (5) 16 41 (13)
NLR[ 3 ? mGPS = 0 23 64 (10) 9 22 (14)
NLR[ 3 ? mGPS[ 0 7 100 (0) 4 0 (0)
\ 0.001
mGPS preoperative modified Glasgow Prognostic score, NLR neutrophil to lymphocyte ratio, OS overall
survival, SE standard error
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carcinomas, may have influenced the survival analysis.
Other potentially curative treatment options, including
upfront surgery and radical chemoradiation, were not
included to reduce heterogeneity, and therefore make it
easier to draw conclusions from the results generated from
a complex patient care pathway. However, given the pre-
sent results, the examination of combination systemic
inflammation scoring as part of EC staging in these other
modalities is warranted. Furthermore, not all patients had
preoperative CRP, albumin, and FBC measured, further
reducing the sample size. Finally, certain pathological and
postoperative variables, e.g. ypTNM stage, LVI, postop-
erative morbidity, etc., which are well-recognized
prognostic factors, were not included in the multivariable
model. This was deliberate as the focus of this work was
the addition of the host SIR to prognostic factors deter-
mined during staging and prior to NAC, which might
influence initial or ongoing management.
CONCLUSION
The present study reports that a pretreatment systemic
inflammation score using a combination of NLR and mGPS
is associated with poorer survival in patients undergoing
treatment with curative intent for ECs. The effective
stratification of 5-year OS when used along with ECOG
performance status and clinical TNM stage reinforces the
importance of staging both the tumor and the host. If val-
idated in prospective studies, such a combined staging
method may prove useful when making multidisciplinary
treatment decisions about whether to submit patients to
aggressive treatment or consider symptomatic manage-
ment. This is of special importance in this patient group
due to the relatively high morbidity associated with NAC
and esophagogastric resections, and the poor long-term
outcomes in those patients with higher clinical stage, poor
performance status, and the presence of significant sys-
temic inflammation.
DISCLOSURES Stephen T. McSorley, Hiu Y.N. Lau, David
McIntosh, Matthew J. Forshaw, Donald C. McMillan, and Andrew B.
Crumley have no disclosures to declare, and no funding was received
for this work.
OPEN ACCESS This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons licence, and indicate
if changes were made. The images or other third party material in this
article are included in the article’s Creative Commons licence, unless
indicated otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons licence and your intended
use is not permitted by statutory regulation or exceeds the permitted
use, you will need to obtain permission directly from the copyright
holder. To view a copy of this licence, visit http://creativecommons.
org/licenses/by/4.0/.
REFERENCES
1. Isdscotland.org. Cancer in Scotland Cancer in Scotland. 2018.
Available at: https://www.isdscotland.org/Health-Topics/Cancer/
Publications/2018-04-24/Cancer_in_Scotland_summary_m.pdf.
Accessed 15 Dec 2018.
2. Cancerresearchuk.org. Survival | Oesophageal cancer | Cancer
Research UK. 2016. Available at: https://www.cancerresearchuk.
org/about-cancer/oesophageal-cancer/survival. Accessed 15 Dec
2018.
3. EBSCO Information Services Record No. T114816. Esophageal and
esophagogastric junction cancer [updated 3 Dec 2018; cited 15 Dec
2018]. Ipswich, MA: DynaMed Plus. Available at: https://www-d
ynamed-com.eproxy.lib.hku.hk/topics/dmp*AN*T114816.
4. Raymond DP. Complications of esophageal resection. In: Post
TW (ed). UpToDate; 2019. https://www.uptodate.com. Accessed
16 Mar 2019.
5. Viklund P, Lindblad M, Lu M, Ye W, Johansson J, Lagergren J.
Risk factors for complications after esophageal cancer resec-
tion. Ann Surg. 2006;243(2):204–11.
6. National Oesophago-Gastric Cancer Audit 2018: An audit of the
care received by people with Oesophago-Gastric Cancer in
England and Wales 2018 Annual Report. Version 2, March 2019.
Available at: https://www.nogca.org.uk/content/uploads/2019/04/
NOGCA-2018-Annual-Report-V2.pdf.
7. Knight W, Zylstra J, Van Hemelrijck M et al. Patterns of recur-
rence in oesophageal cancer following oesophagectomy in the era
of neoadjuvant chemotherapy. BJS Open 2017;1(6):182–90.
8. Crumley A, McMillan D, McKernan M, Going J, Shearer C,
Stuart R. An elevated C-reactive protein concentration, prior to
surgery, predicts poor cancer-specific survival in patients under-
going resection for gastro-oesophageal cancer. Br J Cancer,
2006;94(11):1568–71.
9. Dutta S, Crumley A, Fullarton G, Horgan P, McMillan D.
Comparison of the prognostic value of tumour- and patient-re-
lated factors in patients undergoing potentially curative resection
of oesophageal cancer. World J Surg. 2011;35(8):1861–6.
10. Park JH, Woodley N, McMillan DC, Glen P. Palliative stenting
for oesophagogastric cancer: tumour and host factors and prog-
nosis. BMJ Support Palliat Care. 2019;9(3):332–9.
11. Roxburgh C, McMillan D. Role of systemic inflammatory
response in predicting survival in patients with primary operable
cancer. Future Oncol. 2010;6(1):149–63.
12. McMillan D. The systemic inflammation-based Glasgow Prog-
nostic Score: a decade of experience in patients with
cancer. Cancer Treat Rev. 2013;39(5):534–40.
13. Dolan RD, Lim J, McSorley ST, Horgan, PG, McMillan DC. The
role of the systemic inflammatory response in predicting out-
comes in patients with operable cancer: systematic review and
meta-analysis. Sci Rep. 2017;7:16717.
14. Inamoto S, Kawada K, Okamura R, Hida K, Sakai Y. Prognostic
impact of the combination of neutrophil-to-lymphocyte ratio and
Glasgow prognostic score in colorectal cancer: a retrospective
cohort study. Int J Colorectal Dis. 2019;34:1303–15.
15. Moyes L, McCaffer C, Carter R, Fullarton G, Mackay C, Forshaw
M. Cardiopulmonary exercise testing as a predictor of compli-
cations in oesophagogastric cancer surgery. Ann R Coll Surg
Engl. 2013;95(2):125–30.
16. Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT,
McCargar LJ, et al. Cancer cachexia in the age of obesity:
skeletal muscle depletion is a powerful prognostic factor, inde-
pendent of body mass index. J Clin Oncol. 2013;31(12):1539–47.
730 S. T. McSorley et al.
17. Jomrich G, Paireder M, Kristo I, Baierl A, Ilhan-Mutlu A, Pre-
usser M, et al. High systemic immune-inflammation index is an
adverse prognostic factor for patients with gastroesophageal
adenocarcinoma. Ann Surg. 2019. https://doi.org/10.1097/sla.
0000000000003370.
18. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related
inflammation. Nature. 2008;454(7203):436–44.
19. 19. Hanahan D, Weinberg RA. Hallmarks of cancer: the next
generation. Cell. 2011;144(5):646–74. https://doi.org/10.1016/j.c
ell.2011.02.013.
20. Mantovani A, Ponzetta A, Inforzato A, Jaillon S. Innate immu-
nity, inflammation and tumour progression: double-edged swords.
J Intern Med. 2019;285(5):524–32.
21. Gabay C, Kushner I. Acute-phase proteins and other systemic
responses to inflammation. N Engl J Med. 1999;340(6):448–54.
22. Jaillon S, Galdiero MR, Del Prete D, Cassatella MA, Garlanda C,
Mantovani A. Neutrophils in innate and adaptive immunity.
Semin Immunopathol. 2013;35(4):377–94.
23. Park JH, Watt DG, Roxburgh CS, Horgan PG, McMillan DC.
Colorectal cancer, systemic inflammation, and outcome: staging
the tumor and staging the host. Ann Surg. 2016;263(2):326–36.
24. Laird BJ, Fallon M, Hjermstad MJ, Tuck S, Kaasa S, Klepstad P,
et al. Quality of life in patients with advanced cancer: differential
association with performance status and systemic inflammatory
response. J Clin Oncol. 2016;34(23):2769–75.
25. Park JH, Ishizuka M, McSorley ST, Kubota K, Roxburgh CSD,
Nagata H, et al. Staging the tumor and staging the host: a two
centre, two country comparison of systemic inflammatory
responses of patients undergoing resection of primary operable
colorectal cancer. Am J Surg. 2018;216(3):458–64.
26. Kurzrock R, Hickish T, Wyrwicz L, Saunders M, Wu Q, Stecher
M, et al. Interleukin-1 receptor antagonist levels predict favorable
outcome after bermekimab, a first-in-class true human inter-
leukin-1a antibody, in a phase III randomized study of advanced
colorectal cancer. Oncoimmunology. 2018;8(3):1551651.
27. McDonald JJ, McMillan DC, Laird BJA. Targeting IL-1a in
cancer cachexia: a narrative review. Curr Opin Support Palliat
Care. 2018;12(4):453–9.
28. Amaria RN, Reddy SM, Tawbi HA et al. Neoadjuvant immune
checkpoint blockade in high-risk resectable melanoma. Nat Med
2018;24:1649–54.
29. Forde PM, Chaft JE, Smith KN et al. Neoadjuvant PD-1 blockade
in resectable lung cancer. N Engl J Med 2018;378:1976–86.
Publisher’s Note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
Staging the Tumor and Staging the Host 731
